Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • November 2019
  • Case
  • HBS Case Collection

The Genesis Lab at Novartis

By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
  • Format:Print
  • | Language:English
  • | Pages:26
ShareBar

Abstract

Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down barriers between functions and regions that slow innovation. After advancing to the pitch stage, a panel selected a handful of winning proposals. Winning teams left their roles for 18 months and received the resources and laboratory space to pursue their ideas. By 2018, two cohorts of winners had been selected—one almost at the end of its 18-month tenure and the other soon to begin. Genesis Labs had already overcome several hurdles—for example, scientists at first worried that stepping out of their ordinary role or pitching ideas that were not chosen could end their careers at Novartis. Though the Genesis Labs program ultimately succeeded in attracting many candidates, the company wondered how to further refine it to foster greater agility in Novartis R&D. Should they expand the call for entries? Did it encourage true shoot-the-moon ideas? How often should the program run, and how disruptive should it be to existing teams? What was the best way to reintegrate scientists to prior roles after their 18-month stint as part of Genesis Labs was over? Finally, could such contests be adapted and rolled out in other functions in the organization?

Keywords

Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management

Citation

Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
  • Educators
  • Purchase

About The Authors

Amy C. Edmondson

Technology and Operations Management
→More Publications

Ranjay Gulati

Organizational Behavior
→More Publications

More from the Authors

    • March 2023
    • Faculty Research

    Moderna

    By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
    • March 2023
    • Faculty Research

    Walmart’s Live Better U

    By: Boris Groysberg, Annelena Lobb and Kerry Herman
    • January 2023
    • Faculty Research

    First to Fight? Culture, Tradition and the United States Marine Corps (USMC)

    By: Ranjay Gulati, Akhil Iyer and Joel Malkin
More from the Authors
  • Moderna By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
  • Walmart’s Live Better U By: Boris Groysberg, Annelena Lobb and Kerry Herman
  • First to Fight? Culture, Tradition and the United States Marine Corps (USMC) By: Ranjay Gulati, Akhil Iyer and Joel Malkin
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College